Structure Therapeutics Inc. American Depositary Shares (GPCR)

Structure Therapeutics is developing an oral weight-management drug called aleniglipron, targeting the hot obesity treatment market. The company's success depends on strong clinical trial results, with potential for significant stock price movement based on its phase 2 study outcomes.

Structure Therapeutics, a clinical-stage biopharmaceutical company, announced two late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions. The presentations will include preclinical data for their oral small molecule amylin agonist, ACCG-2671, and their oral small molecule GLP-1 receptor agonist, GSBR-5595.

Pfizer's challenging period may be turning around with strong Q1 performance and potential changes under new leadership. Learn more about PFE stock's buy rating.

Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.

On Monday, Structure Therapeutics Inc. (NASDAQ:GPCR) revealed 12-week topline obesity data from its Phase 2a study of GSBR-1290. In the Phase 2a obesity study, GSBR-1290 demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks. Cantor Fitzgerald maintains its bullish views on Structure Therapeutics and keeps the Overweight rating with a price target of $65. The analyst says, “now have more conviction that ‘1290 is very competitive with Eli Lilly And Co’s (NYSE:LLY) orforglipron on efficacy and data from ...Full story available on Benzinga.com